#United States #New York #Cyclo Therapeutics #Pomerantz LLP #Rafael Holdings

Investigation of Rafael Holdings, Inc.

Pomerantz LLP has initiated an investigation concerning possible securities fraud and unethical business practices related to Rafael Holdings, Inc. (NYSE: RFL). This action is particularly relevant for investors who experienced significant financial loss after a recent downturn in the company's stock value following the announcement of unfavorable clinical trial results.

On September 30, 2026, Rafael Holdings released a press statement detailing the outcomes of the pivotal Phase 3 TransportNPC™ study conducted by its subsidiary, Cyclo Therapeutics, LLC. The study evaluated the efficacy and safety of Trappsol® Cyclo™, a treatment aimed at Niemann-Pick Disease Type C (NPC). However, the results indicated that the primary endpoint did not achieve statistical significance. This disappointing outcome led to a drastic decline in Rafael's stock price, which plummeted by 34.98%, closing at $1.32 per share the same day.

The critical investigation raises serious concerns about whether Rafael Holdings and its executives acted with full transparency regarding the efficacy of the drug, potentially misleading investors regarding the success of the trial. Following such revelations, it is crucial for investors to understand their rights and options, especially regarding their financial investments in a company that may have concealed vital information about its products. They are encouraged to contact attorney Danielle Peyton at Pomerantz LLP for guidance and to participate in the ongoing investigation.

Founded over 85 years ago by the late Abraham L. Pomerantz, Pomerantz LLP is recognized for its leadership in securities class actions and handles cases of corporate misconduct. With offices across major cities including New York, Chicago, and London, the firm boasts a reputation for recovering substantial damages on behalf of investors.

Investors are advised to act swiftly and may contact Pomerantz LLP to discuss their potential claims and participation in any class actions related to Rafael Holdings. Understanding the full scope of the investigation and legal options is essential in such times of uncertainty.

As the situation develops, shareholders are reminded of the importance of vigilance regarding company communications and performance, particularly in the evolving landscape of biopharmaceutical investments.

Overall, this incident serves as a cautionary tale, underscoring the critical role that transparency plays in maintaining investor trust and the necessity for robust legal representation in the face of possible corporate malfeasance.